Status quo und Perspektiven der systemischen Therapie der atopischen Dermatitis

详细信息    查看全文

• 作者：T. Biedermann ; Prof. Dr. T. Werfel
• 关键词：Systemtherapie ; Cyclosporin ; Dupilumab ; Off label ; Zielmoleküle ; Systemic treatment ; Cyclosporine ; Dupilumab ; Off ; label use ; Molecular targeted therapy
• 刊名：Der Hautarzt
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：66
• 期：2
• 页码：108-113
• 全文大小：695 KB
• 参考文献：1. Baquerizo Nole KL, Yim E, Keri JE (2014) Probiotics and prebiotics in dermatology. J Am Acad Dermatol 71:814-21 CrossRef
  2. Beck LA, Thaci D, Hamilton JD et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130-39 CrossRef
  3. Belloni B, Ziai M, Lim A et al (2007) Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120:1223-225 CrossRef
  4. Bieber T, Straeter B (2015) Off-label prescriptions for atopic dermatitis in Europe. Allergy 70:6-1 CrossRef
  5. Eyerich S, Onken AT, Weidinger S et al (2011) Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. N Engl J Med 365:231-38 CrossRef
  6. Gueniche A, Knaudt B, Schuck E et al (2008) Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 159:1357-363 CrossRef
  7. Haeck IM, Knol MJ, Ten Berge O et al (2011) Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 64:1074-084 CrossRef
  8. Hamilton JD, Suarez-Farinas M, Dhingra N et al (2014) Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 134:1293-300 CrossRef
  9. Harskamp CT, Armstrong AW (2013) Immunology of atopic dermatitis: novel insights into mechanisms and immunomodulatory therapies. Semin Cutan Med Surg 32:132-39
  10. Heil PM, Maurer D, Klein B et al (2010) Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course -a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 8:990-98
  11. Ibler KS, Jemec GB (2014) Novel investigational therapies for atopic dermatitis. Expert Opin Investig Drugs 24:1-
  12. Jacobi A, Manger B, Schuler G et al (2003) Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders. J Dtsch Dermatol Ges 1:259-72 CrossRef
  13. Kaesler S, Volz T, Skabytska Y et al (2014) Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10. J Allergy Clin Immunol 134:92-9 CrossRef
  14. Lane JE, Cheyney JM, Lane TN et al (2006) Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54:68-2 CrossRef
  15. Mrowietz U, Klein CE, Reich K et al (2009) Cyclosporine therapy in dermatology. J Dtsch Dermatol Ges 7:474-79
  16. Navarini AA, French LE, Hofbauer GF (2011) Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 128:1128-130 CrossRef
  17. O’Regan GM, Sandilands A, McLean WH et al (2009) Filaggrin in atopic dermatitis. J Allergy Clin Immunol 124:R2–R6 CrossRef
  18. Oldhoff JM, Darsow U, Werfel T et al (2006) No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 141:290-94 CrossRef
  19. Puya R, Alvarez-Lopez M, Velez A et al (2012) Trea
• 作者单位：T. Biedermann (1)
  Prof. Dr. T. Werfel (2)
  
  1. Klinik und Poliklinik für Dermatologie und Allergologie, Biedersteinerstra?e 29, 80802, München, Deutschland
  2. Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
  
• 刊物主题：Dermatology; Immunology; Allergology; Proctology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1432-1173

文摘

Currently the only approved drug available for the systemic therapy of atopic dermatitis is cyclosporine; however, based on current data from published studies, azathioprine, methotrexate, and mycophenolate mofetil or mycophenolic acid can be administered off-label. Some biologics on the market that have been approved for other indications (ustekinumab, rituximab, tocilizumab) have been successfully used in a few patients with atopic dermatitis. The world’s first prospective controlled studies with the biologic human anti-IL4R antibody dupilumab for the indication “atopic dermatitis-were published in 2014. These motivated (1) to extend the studies to dupilumab and (2) to clinically test antagonization of other target molecules of TH2 polarized, atopic inflammation, e.g., IL-13, IL-31, IL-22, TSLP, and CRTH2. A number of clinical trials are currently recruiting in this area and will provide interesting new insights for future therapeutic approaches in atopic dermatitis